Key Points
- Glaukos director Gilbert Kliman sold 2,500 shares at an average price of $190, generating approximately $475,000. The transaction reduced his direct holdings by 6.26% to 37,406 shares.
- Glaukos reported 49.6% year-over-year revenue growth to $185.6 million and a quarterly loss of $0.14 per share, outperforming analysts’ expectations, though the company remains unprofitable.
- Analyst sentiment remains favorable, with a “Moderate Buy” consensus and recent price-target increases, supported by growth in the iDose TR implant, Epioxa launch and broader ophthalmology pipeline.
Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Gilbert Kliman sold 2,500 shares of the business's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the sale, the director directly owned 37,406 shares of the company's stock, valued at approximately $7,107,140. This trade represents a 6.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Glaukos Stock Performance
Glaukos stock opened at $185.25 on Friday. The stock's 50-day moving average is $156.20 and its 200-day moving average is $131.24. The company has a market cap of $10.93 billion, a price-to-earnings ratio of -57.00 and a beta of 0.78. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $191.62.
Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The business had revenue of $185.61 million during the quarter, compared to analysts' expectations of $150.93 million. During the same quarter in the previous year, the business earned ($0.24) EPS. The company's revenue for the quarter was up 49.6% on a year-over-year basis. Equities analysts anticipate that Glaukos Corporation will post -0.35 earnings per share for the current year.
Glaukos News Roundup
Here are the key news stories impacting Glaukos this week:
- Positive Sentiment: BTIG raised its price target to $202 from $193 and maintained a “Buy” rating, implying about 9% upside from the referenced $185.25 price. The upgrade reflects continued confidence in Glaukos’ growth outlook. Benzinga report
- Positive Sentiment: Analyst estimates from Zacks Research were raised broadly, including FY2027 EPS to $0.45 from $0.38 and FY2028 EPS to $1.70 from $1.56. Forecasts for several 2027 and 2028 quarters were also increased, signaling expectations for a transition toward stronger earnings. Glaukos analyst estimates
- Positive Sentiment: Glaukos’ iDose TR glaucoma implant and the Epioxa launch are driving record growth and contributed to higher 2026 guidance. Investors are also responding to the company’s expanding ophthalmology platform, product pipeline and potential for margin expansion. Zacks growth outlook article
- Neutral Sentiment: The company recently reported revenue of $185.6 million, up 49.6% year over year, and a quarterly loss of $0.14 per share that was better than expected. Glaukos remains unprofitable, but analysts expect positive EPS in future periods as revenue scales.
- Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190. The sale reduced his direct ownership by 6.26%, although he still held 37,406 shares afterward. SEC insider trading filing
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the business. First Horizon Corp boosted its stake in Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 223 shares during the last quarter. Allworth Financial LP bought a new stake in shares of Glaukos in the 2nd quarter worth about $28,000. Los Angeles Capital Management LLC bought a new stake in shares of Glaukos in the 4th quarter worth about $28,000. Larson Financial Group LLC raised its stake in shares of Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 132 shares in the last quarter. Finally, Parallel Advisors LLC raised its stake in shares of Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier's stock valued at $40,000 after purchasing an additional 226 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.
Analyst Ratings Changes
Several research firms have commented on GKOS. Piper Sandler reissued an "overweight" rating and issued a $195.00 price objective (up from $165.00) on shares of Glaukos in a research report on Thursday, July 30th. UBS Group started coverage on Glaukos in a research report on Tuesday, July 28th. They issued a "neutral" rating and a $150.00 target price for the company. BTIG Research increased their target price on Glaukos from $193.00 to $202.00 and gave the company a "buy" rating in a research note on Thursday. Needham & Company LLC raised their target price on Glaukos from $150.00 to $201.00 and gave the company a "buy" rating in a report on Thursday, July 30th. Finally, JPMorgan Chase & Co. boosted their price target on Glaukos from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Thursday, April 30th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Glaukos has an average rating of "Moderate Buy" and an average price target of $178.08.
Read Our Latest Research Report on GKOS
About Glaukos
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
